Showing results (561-570 of 735) with videos related to
Sort By:
Pageof 74
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.The New England Journal of Medicine|September 12, 2017
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.Clinical Kidney Journal|June 3, 2026
Environmental footprint of peritoneal dialysis in Europe: a comparative life cycle assessment across four European centresAbass Fehintola, Zuzanna Jakubowska, Malgorzata Kepska-Dzilinska, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 TrialMehmet A Bilen, Brian I Rini, Martin H Voss, et al.The Lancet. Oncology|April 1, 2019
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trialDirk Schadendorf, Axel Hauschild, Mario Santinami, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerBhavna Oza, Tim Eisen, Eleni Frangou, et al.The New England Journal of Medicine|April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Jacob Schachter, Georgina V Long, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2018
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III MelanomaAxel Hauschild, Reinhard Dummer, Dirk Schadendorf, et al.Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2024
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial DataGeorgina V Long, Evan J Lipson, F Stephen Hodi, et al.Pageof 74